Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study.

MLA

Bettiol, Alessandra, et al. “Sequential Rituximab and Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A European Multicentre Observational Study.” Annals of the Rheumatic Diseases, vol. 81, no. 12, Dec. 2022, pp. 1769–72. EBSCOhost, https://doi.org/10.1136/ard-2022-222776.

APA

Bettiol, A., Urban, M. L., Bello, F., Fiori, D., Mattioli, I., Lopalco, G., Iannone, F., Egan, A., Dagna, L., Caminati, M., Negrini, S., Bargagli, E., Folci, M., Franceschini, F., Padoan, R., Flossmann, O., Solans, R., Schroeder, J., André, M., … Emmi, G. (2022). Sequential rituximab and mepolizumab in eosinophilic granulomatosis with polyangiitis (EGPA): a European multicentre observational study. Annals of the Rheumatic Diseases, 81(12), 1769–1772. https://doi.org/10.1136/ard-2022-222776

Chicago

Bettiol, Alessandra, Maria Letizia Urban, Federica Bello, Davide Fiori, Irene Mattioli, Giuseppe Lopalco, Florenzo Iannone, et al. 2022. “Sequential Rituximab and Mepolizumab in Eosinophilic Granulomatosis with Polyangiitis (EGPA): A European Multicentre Observational Study.” Annals of the Rheumatic Diseases 81 (12): 1769–72. doi:10.1136/ard-2022-222776.